Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Telomir Pharmaceuticals, Inc. - Common Stock (NQ:TELO)

1.340 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 99,860
Open 1.340
Bid (Size) 1.340 (200)
Ask (Size) 1.400 (1,600)
Prev. Close 1.340
Today's Range 1.340 - 1.340
52wk Range 1.120 - 5.400
Shares Outstanding 34,380,971
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
Via ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Favorable IND-Enabling GLP Safety Results for Telomir-1
Via Investor Brand Network

Performance

YTD
N/A
N/A
1 Month
-2.2%
-2.2%
3 Month
-5.6%
-5.6%
6 Month
+16.5%
+16.5%
1 Year
-68.3%
-68.3%

More News

Read More
News headline image
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development
Via ACCESS Newswire
News headline image
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells
Via ACCESS Newswire
News headline image
TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death ↗
Via Stocktwits
Why Telomir Pharmaceuticals Stock Is Rising 40% Premarket Today ↗
Via Stocktwits
News headline image
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells
Via ACCESS Newswire
News headline image
Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line
Via ACCESS Newswire
News headline image
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo
Via ACCESS Newswire
News headline image
Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth
Via ACCESS Newswire
News headline image
Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
Thursday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Telomir Pharmaceuticals Touts Promising Action From Its Lead Breast Cancer Drug ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
Which stocks are moving before the opening bell on Thursday? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells
Via ACCESS Newswire
News headline image
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance
Via ACCESS Newswire
News headline image
Stock Market Today: Dow Jones, Nasdaq Futures Slip Amid Delay In Trade Deficit Data During Shutdown—Trilogy Metals, AMD, Applovin In Focus ↗
Via Benzinga
Topics Stocks
News headline image
Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
McCormick, Telomir Pharmaceuticals And 3 Stocks To Watch Heading Into Tuesday ↗
Via Benzinga

Frequently Asked Questions

Is Telomir Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Telomir Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Telomir Pharmaceuticals, Inc. - Common Stock trade on?
Telomir Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Telomir Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Telomir Pharmaceuticals, Inc. - Common Stock is TELO on the Nasdaq Stock Market
What is the current price of Telomir Pharmaceuticals, Inc. - Common Stock?
The current price of Telomir Pharmaceuticals, Inc. - Common Stock is 1.340
When was Telomir Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Telomir Pharmaceuticals, Inc. - Common Stock was at 01/02/26 04:00 PM ET
What is the market capitalization of Telomir Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Telomir Pharmaceuticals, Inc. - Common Stock is 46.07M
How many shares of Telomir Pharmaceuticals, Inc. - Common Stock are outstanding?
Telomir Pharmaceuticals, Inc. - Common Stock has 46M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.